(Q38148588)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Epigenetics of melanoma: implications for immune-based therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Elisabetta Fratta

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Alessia Covre

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Sandra Coral

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Luca Sigalotti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Giulia Parisi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

1103-1116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

Epigenetics in human disease and prospects for epigenetic therapy

26 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetic modifications in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Genomic DNA methylation: the mark and its mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The biology of cancer testis antigens: putative function, regulation and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

DNA methylation: roles in mammalian development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Molecular coupling of DNA methylation and histone methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

DNA methylation and methyl-CpG binding proteins: developmental requirements and function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Regulated nucleosome mobility and the histone code.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Functional consequences of histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetic protein families: a new frontier for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The language of covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Cracking the death code: apoptosis-related histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetic regulation by histone methylation and histone variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Chromatin modifications and their function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MicroRNAs and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MicroRNAs in tumorigenesis: a primer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

miTarget: microRNA target gene prediction using a support vector machine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetics and microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetic changes in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Hypomethylation distinguishes genes of some human cancers from their normal counterparts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Overexpression of DNA methyltransferase 1 and its biological significance in primary hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetic reprogramming as a key contributor to melanocyte malignant transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

An essential role for DNA methyltransferase 3a in melanoma tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Gene silencing in cancer in association with promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Hereditary cancer: two hits revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Aberrant DNA methylation in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

21 January 2018

Main roads to melanoma

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Frequent p16-independent inactivation of p14ARF in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

CpG island methylator phenotype predicts progression of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

CpG island methylation profiling in human melanoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The Drosophila Polycomb-group gene Enhancer of zeste contains a region with sequence similarity to trithorax

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The Drosophila trithorax proteins contain a novel variant of the nuclear receptor type DNA binding domain and an ancient conserved motif found in other chromosomal proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Repression of E-cadherin by the polycomb group protein EZH2 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The INK4a/ARF network in tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

miR-148 regulates Mitf in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Up-regulation of miR-182 expression after epigenetic modulation of human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MicroRNA-221 and -222 pathway controls melanoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MicroRNA-9 up-regulates E-cadherin through inhibition of NF-κB1-Snail1 pathway in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MicroRNA miR-125b induces senescence in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MicroRNAs impair MET-mediated invasive growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetic regulation of microRNA-375 and its role in melanoma development in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

DNA methyltransferase inhibitors and the development of epigenetic cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Recent advances in histone deacetylase targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Histone acetylation in gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Demethylating agents in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The promises and pitfalls of epigenetic therapies in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Induction of MAGE-3 expression in lung and esophageal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

MHC class I antigens and immune surveillance in transformed cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Methylation-regulated expression of HLA class I antigens in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

HLA class I antigen abnormalities and immune escape by malignant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

An epigenetic vaccine model active in the prevention and treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

An epigenetically altered tumor cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Angiostatic activity of DNA methyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.108

21 January 2018

Identifiers

DOI

10.2217/IMT.13.108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24088079%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference